
OptiNose, Inc. (NASDAQ: OPTN), relating to the proposed merger with Paratek Pharmaceuticals. Under the terms of the agreement, OptiNose shareholders will have the right to receive $9.00 in cash per share of stock owned, and one contractual contingent value right.